| 11 Nov 2008 | Crucell Announces Third Quarter 2008 Results |
| 04 Nov 2008 | Crucell to Release Q3 2008 Earnings on Tuesday, November 11, 2008 |
| 21 Oct 2008 | Crucell Doubles Production of Quinvaxem® in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth |
| 17 Oct 2008 | Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa |
| 03 Oct 2008 | Crucell Receives NIAID/NIH Contract for Development of Ebola and Marburg Vaccines |
| 01 Oct 2008 | Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US |
| 29 Sep 2008 | DSM and Crucell announce another key achievement for PER.C6® Technology; Scale up of high-titer Fed-Batch Process to 250 Liters |
| 26 Sep 2008 | Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing |
| 25 Sep 2008 | Lonza and Crucell enter into long term agreement |
| 23 Sep 2008 | New contracts awarded for Quinvaxem® and Hepavax-Gene® |
| 18 Sep 2008 | Crucell Signs Exclusive License Agreement with Talecris Biotherapeutics |
| 26 Aug 2008 | Crucell to move Dukoral® and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites |
| 12 Aug 2008 | Crucell Announces Second Quarter 2008 Results |
| 05 Aug 2008 | Crucell to Release Q2 2008 Earnings on Tuesday, August 12, 2008 |
| 25 Jun 2008 | DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6® Cell Line Proteins |
| 16 Jun 2008 | DSM and Crucell Announce Record Achievement in PER.C6® Technology |
| 30 May 2008 | Crucell 2008 Annual General Meeting of Shareholders |
| 20 May 2008 | Crucell Announces Research License Agreement with Bioceros on STAR® Technology |
| 13 May 2008 | Crucell Announces First Quarter 2008 Results |
| 13 May 2008 | Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines |
| 06 May 2008 | Crucell to Release Q1 2008 Earnings on Tuesday, May 13, 2008 |
| 29 Apr 2008 | Crucell Announces STAR® Research License Agreement with Toyobo Gene Analysis Co. LTD. |
| 09 Apr 2008 | Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa |
| 08 Apr 2008 | Crucell Announces STAR® Research License Agreement with Celltrion, Inc. |
| 03 Apr 2008 | Crucell Announces First in Man Study with New Adenovirus Vector |
| 31 Mar 2008 | Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US |
| 25 Mar 2008 | Crucell Announces STAR® Research License Agreement with Medarex Inc |
| 17 Mar 2008 | Crucell and DSM Biologics Announce Additional PER.C6® Licensing Agreement with MorphoSys |
| 12 Mar 2008 | Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London |
| 11 Mar 2008 | DSM and Crucell Announce PER.C6® Technology Milestone |
| 03 Mar 2008 | Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals |
| 12 Feb 2008 | Crucell Announces Fourth Quarter and Full Year 2007 Results |
| 11 Feb 2008 | Crucell Nominates Cees de Jong as Management Board Member |
| 31 Jan 2008 | Crucell to Release Q4/FY 2007 Earnings on Tuesday, February 12, 2008 |
| 30 Jan 2008 | Crucell Nominates Steve Davis as Supervisory Board Member |
| 16 Jan 2008 | Crucell Reacts to Recent CEVEC Press Release |
| 14 Jan 2008 | Crucell Announces STAR® Technology Research License with Korean-based ISU ABXIS |
| 09 Jan 2008 | TRADING UPDATE |
| 03 Jan 2008 | Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies |
About Us
